The short version of drug affinity complex fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-04 and is reviewed periodically as new material appears.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
=== Burger Chef trademark dispute === In January 2007, Hardee's had a challenge filed against it with the U.S. Patents and Trademarks Office by River West Brands, LLC of Chicago for the use of the Burger Chef trademark and name. Shortly thereafter, Hardee's reissued the Burger Chef Big Shef sandwich in Terre Haute, Indiana, as a trial offering and later in additional Indiana markets and Dayton, Ohio, for a limited time. The reissue of the Big Shef has also used the Burger Chef name and logo in advertisements in the markets in which it is offered, and has claimed to provide Burger Chef fans with their Big Shef "fix". On April 16, 2009, River West Brands dropped their petition for cancellation and both parties agreed to pay their own attorney's fees.
Rose Pharma is a private company that was founded in 2003 as Gastrotech Pharma and is located in Copenhagen, Denmark. The company is led by CEO Leif Helth Jensen, who is, together with Michael Forer and Florian Schönharting, also member of the Board of Directors. Rose Pharma is a clinical stage biotechnology company focused on the development of novel treatments for IBS and anorexia/cachexia associated with cancer and other major pathologies.
=== Budget and taxes === In May 2025, Kiggans voted for the One Big Beautiful Bill Act. Kiggans advocated to maintain appropriated funds for NASA's Wallops Flight Facility and Langley Research Center in the 2026 federal budget. She argues that these locations are "prized possession for the Commonwealth" and that "the work that's going on there from the defense side, but also on the private industry side, [...] with places like Rocket Lab and Firefly, and Northrop Grumman is there."
Sources: en.wikipedia.org
Raleigh is the home of Raleigh Kubb, both a competitive and non-competitive kubb club. Raleigh Kubb hosts kubb tournaments benefitting various charities in the Raleigh area. The Raleigh Parks and Recreation Department offers a wide variety of leisure opportunities at more than 200 sites throughout the city, which include: 8,100 acres (33 km2) of park land, 78 mi (126 km) of greenway, 22 community centers, a BMX championship-caliber race track, 112 tennis courts among 25 locations, 5 public lakes, and 8 public aquatic facilities. The park system includes the historic Pullen Park, the oldest public park in North Carolina. The J. C. Raulston Arboretum, an 8-acre (32,000 m2) arboretum and botanical garden in west Raleigh administered by North Carolina State University, maintains a year-round collection that is open daily to the public without charge.
==== Late onset ==== Late-onset Alzheimer's is about 70% heritable. Most cases of Alzheimer's are not familial, and so they are termed sporadic Alzheimer's disease. Of the cases of sporadic Alzheimer's disease, most are classified as late onset where they are developed after the age of 65 years. The strongest genetic risk factor for sporadic Alzheimer's disease is APOEε4. APOEε4 is one of the three major alleles of apolipoprotein E (APOE). APOE plays a major role in lipid-binding proteins in lipoprotein particles and the ε4 allele disrupts this function. Between 40% and 80% of people with Alzheimer's disease possess at least one APOEε4 allele. The APOEε4 allele increases the risk of the disease by three times in heterozygotes and by 15 times in homozygotes. Like many human diseases, environmental effects and genetic modifiers result in incomplete penetrance. For example, Nigerian Yoruba people do not show the relationship between the dose of APOEε4 and incidence or age-of-onset for Alzheimer's disease seen in other human populations.
Throat culture Anti-DNAse B titre (peaks at 8–12 weeks after infection) Anti-streptolysin O titre (peaks at 3–5 weeks) None of these tests are 100% reliable, particularly when the infection was some months previously. Further testing is directed more towards alternative diagnoses and other manifestations of rheumatic fever:
== Motorsport and racing scandals == 1994 Formula One cheating controversy – a number of allegations of cheating were thrown during the 1994 Formula One season, particularly to the Benetton team. 2007 NASCAR Gatorade Duel scandal – three various incidents related to the Gatorade Duel. 2007 Formula One espionage controversy, commonly known as Spygate – an incident in which Scuderia Ferrari mechanic Nigel Stepney passed on a secret document to Mike Coughlan of McLaren. 2008 race fixing controversy, also known as Crashgate – it was surrounded by allegations in Formula One that driver Nelson Piquet Jr. deliberately crashed in the 2008 Singapore Grand Prix to help his Renault teammate Fernando Alonso win. Felipe Massa is pursuing legal action against Formula One Management, the FIA and Bernie Ecclestone for a sum of £64m over Crashgate as he believes the FIA should have voided all points awarded in the Singapore Grand Prix, which would have led to him being 2008 World Champion. A High Court of justice in London has ruled that the case can now go to trial. 2013 Federated Auto Parts 400 – in the final Sprint Cup race, before the field was set for the 2013 Chase for the Sprint Cup, three teams—Michael Waltrip Racing, Penske Racing and Front Row Motorsports—were found to have extensively manipulated the race finish in an attempt to secure Chase places for MWR driver Martin Truex Jr. and Penske driver Joey Logano.
Sources: en.wikipedia.org
=== Reduction === Metal carbonyls react with reducing agents such as metallic sodium or sodium amalgam to give carbonylmetalate (or carbonylate) anions. Polynuclear or electron-imprecise clusters add the reductant to give mononuclear anions:
== Side effects == Like ketamine, etoxadrol produces increases in heart rate and respiratory rate. Etoxadrol may also cause vomiting. At high enough doses, etoxadrol also exhibits effects on the muscular system such as convulsions or loss of the righting reflex. When administered in excess, etoxadrol can be lethal on the respiratory system. Monkeys given extremely high (> 20 mg/kg) doses of etoxadrol died of apparent respiratory failure. Etoxadrol produces a wide variety of dreams, ranging from pleasant to frightening or aversive. Approximately half of patients given etoxadrol report pleasant dreams, 25% report unpleasant dreams, and the remaining 25% experience no dreams at all. Such dreams were frequently described as “floating,” “puffy” or “out of this world." Dreams and hallucinations may persist for as long as 18 to 24 hours. In rare cases, etoxadrol can induce periods of psychotic activity during this recovery period. In the brain, etoxadrol slows down the synthesis of serotonin to 50-60% of control rates and speeds up the rate of dopamine synthesis by up to 200% of the normal rate 4–6 hours after intravenous administration. Like a number of other drugs (e.g. cocaine), etoxadrol has been found to exhibit reinforcing properties. Monkeys will self-administer etoxadrol, dexoxadrol or PCP in a lever-pressing paradigm.
Calculations in 2007 expected that copernicium may be a semiconductor with a band gap of around 0.2 eV, crystallizing in the hexagonal close-packed crystal structure. However, calculations in 2017 and 2018 suggested that copernicium should be a noble metal at standard conditions with a body-centered cubic crystal structure: it should hence have no band gap, like mercury, although the density of states at the Fermi level is expected to be lower for copernicium than for mercury. 2019 calculations then suggested that in fact copernicium has a large band gap of 6.4 ± 0.2 eV, which should be similar to that of the noble gas radon (predicted as 7.1 eV) and would make it an insulator; bulk copernicium is predicted by these calculations to be bound mostly by dispersion forces, like the noble gases. Like mercury, radon, and flerovium, but not oganesson (eka-radon), copernicium is calculated to have no electron affinity.
== Collection of tissues == Histopathological examination of tissues starts with surgery, biopsy, or autopsy. The tissue is removed from the body or plant, and then, often following expert dissection in the fresh state, placed in a fixative which stabilizes the tissues to prevent decay. The most common fixative is 10% neutral buffered formalin (corresponding to 3.7% w/v formaldehyde in neutral buffered water, such as phosphate buffered saline).
In March 2007, in the final verdict by the Supreme Court of Cassation, stated that "in the years of 1994 to 1998 there was no ascertained positive case of doping substances by Juventus players, that the purchase of erythropoietin or its administration to the athletes of the club does not emerge from any act of the trial, and that the same expert had identified the possibility of an administration of erythropoietin in distant terms from the sure evidence ("very probable" and in two cases "practically certain"): it is that therefore, the judgement of probability and not of certainty, did not allow for a statement of responsibility." The verdict also went on to say: "In response to the conclusion taken, the territorial court notes that there were no deferred values higher than the limits set in the various antidoping protocols and that the situation of the Juventus players, both with reference to the average hematological values, and in relation to that of material balance, did not differ from the national average population.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.